NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

Kab,

I respect what you're saying, and I certainly may be wrong, but I still believe that what we're doing may be recognized as a new paradigm in the treatment of cancer. If that should occur, I believe the sky is truly the limit.

In terms of a buyout or partnership price, if LP has in fact shared the data under confidentiality with interested companies, it wouldn't surprise me if they've already agreed to a price at which such an agreement would be announced. Of course that price would have to be predicated on the share price reaching some figure, at least half the price they're offering, and perhaps as much as 70% of it. The key would be reaching that triggering price.

When I first invested in the stock many were saying they believed that LP would sell for nothing under $20 billion, if anything I believe most would say she wants more than that today. With some dilution, let's say our O/S reaches 1.5 billion. If we had a share price that reached double digits our market cap would reach the range where a partner buying in, or a company buying us out, could justify a share price that equated to over a $20 billion market cap. I'm not saying it will, or must happen in the next year, but I certainly believe it's possible. I hope it's a partnership, but I don't believe anyone would want to defeat a buyout offer for $20 billion or more unless the share price were nearly there without it. No telling how high a bidding war could take us, but if others believe it's a new paradigm and that it will work in many forms of cancer, a $100 billion offer would truly be a steal.

I believe that the vaccine has been used in a few other cancers, and results have been encouraging. Of course one or a few say breast cancer patients who appear to improve after its use is only considered anecdotal evidence. Expand that to 50 and perhaps you can get insurance to pay. Get it well above 100 and regulatory approval would certainly be possible. This company can potentially go as far as they wish to take it as long as the data continues to be positive. By itself, I believe approval for only GBM could be worthy of a $20 billion market cap in time, but what if it does work in other cancers, and what if DCVax-Direct does too.

Gary